MedTrace Logo

Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)

NCT00681733 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-05-21

No results posted yet for this study

Summary

1. To assess the metabolic factors in lean and obese patients with NASH.
2. To compare the efficacy of pentoxifylline versus pioglitazone on the metabolic profile and liver histology of NASH patients.

Conditions

  • Metabolic Parameters and Liver Histology

Interventions

DRUG

Pioglitazone

Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose

DRUG

Pioglitazone

30 mg OD

DRUG

Pentoxifylline

1200 mg/d

Sponsors & Collaborators

  • Govind Ballabh Pant Hospital

    lead OTHER_GOV

Principal Investigators

  • Barjesh Ch Sharma, MD, DM · G B Pant Hospital Hospital, New Delhi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681733 on ClinicalTrials.gov